title: Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association.
abstract: The term "fat" may refer to lipids as well as the cells and tissue that store lipid (ie, adipocytes and adipose tissue). "Lipid" is derived from "lipos," which refers to animal fat or vegetable oil. Adiposity refers to body fat and is derived from "adipo," referring to fat. Adipocytes and adipose tissue store the greatest amount of body lipids, including triglycerides and free cholesterol. Adipocytes and adipose tissue are active from an endocrine and immune standpoint. Adipocyte hypertrophy and excessive adipose tissue accumulation can promote pathogenic adipocyte and adipose tissue effects (adiposopathy), resulting in abnormal levels of circulating lipids, with dyslipidemia being a major atherosclerotic coronary heart disease risk factor. It is therefore incumbent upon lipidologists to be among the most knowledgeable in the understanding of the relationship between excessive body fat and dyslipidemia. On September 16, 2012, the National Lipid Association held a Consensus Conference with the goal of better defining the effect of adiposity on lipoproteins, how the pathos of excessive body fat (adiposopathy) contributes to dyslipidemia, and how therapies such as appropriate nutrition, increased physical activity, weight-management drugs, and bariatric surgery might be expected to impact dyslipidemia. It is hoped that the information derived from these proceedings will promote a greater appreciation among clinicians of the impact of excess adiposity and its treatment on dyslipidemia and prompt more research on the effects of interventions for improving dyslipidemia and reducing cardiovascular disease risk in overweight and obese patients.
authors.affiliation: Louisville Metabolic and Atherosclerosis Research Center, 3288 Illinois Avenue, Louisville, KY 40213, USA. hbaysmd@aol.com
authors.forename: Harold E
authors.initials: HE
authors.lastname: Bays
authors.forename: Peter P
authors.initials: PP
authors.lastname: Toth
authors.forename: Penny M
authors.initials: PM
authors.lastname: Kris-Etherton
authors.forename: Nicola
authors.initials: N
authors.lastname: Abate
authors.forename: Louis J
authors.initials: LJ
authors.lastname: Aronne
authors.forename: W Virgil
authors.initials: WV
authors.lastname: Brown
authors.forename: J Michael
authors.initials: JM
authors.lastname: Gonzalez-Campoy
authors.forename: Steven R
authors.initials: SR
authors.lastname: Jones
authors.forename: Rekha
authors.initials: R
authors.lastname: Kumar
authors.forename: Ralph
authors.initials: R
authors.lastname: La Forge
authors.forename: Varman T
authors.initials: VT
authors.lastname: Samuel
mesh_terms: D050154:Adiposity / Q000187:drug effects / Q000502:physiology*; D003245:Consensus Statements as Topic; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology; D050171:Dyslipidemias / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology*; D006801:Humans; D007333:Insulin Resistance / Q000502:physiology; D009765:Obesity / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology*; D014280:Triglycerides / Q000097:blood
chemical_list: D014280:Triglycerides
keywords: Adiposity; Adiposopathic dyslipidemia; Adiposopathy; Dyslipidemia; High-density lipoprotein; Insulin resistance; Low-density lipoprotein; Obesity; Triglycerides; Type 2 diabetes mellitus